os X., Listing J., Brandt J. et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with tumor necrosis factor alpha receptor fusion protein etanercept. Artr Rheum 2005; 52: 1216-23.
.Braun J., Bollow M., Remlinger G. et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998; 41: 58-67.
.Breban M., Vignon E., Claudepierre P. Et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 2002; 41: 1280-5.
34.Davis JC, van der Heijde D., Braun J. et al. Recombinant Human Tumor Necrosis Factor Receptor (Etanercept) for Treating Ankylosing Spondylitis. A Randomized, Controlled Trial. Arthr amp; Rheum 2003; 48: 3230-6.
. Feldman M., Brennan F., Maini R.N. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 1996; 14: 397-440.
. Fox D.A. The role of T cells in the immunopathogenesis of rheumatoid arthritis - New perspectives. Arthr Rheum 1997; 40: 598-609.
. Haibel H., Rudwaleit M., Heldmann F. et al. Efficacy of adalimumab in the treatment of preradiographic axial spondyloarthritis results of a 12-week randomized controlled trial. Arthritis Rheum +2008; 58 (7): 1981-91.
. Kempeni J. Preliminary results of early clinical trials with the fully human anti-TNF а monoclonal antibody D2E7. Ann Rheum Dis 1999; 58 (l.1): 170-2.
. Kiltz U., van der Heijde D., Mielants H. et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis: the patient version. Ann Rheum Dis +2009 Sep; 68 (9): 1381-1386.
. Sieper J. et al. RHAPSODY. Poster report, EULAR 2008, SAT 0267.
. Van der Heijde D., Dijkmans B., Geusens P. et al. Efficacy and safety of infliximab in patients with ankylosing spondilitis. Results of a randomized, placebo controlled trial (ASSERT). Arthritis Rhum 2005; 52: 582-91.
42.Van der Heijde D., Kivitz A., Schiff M.H. et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54,2136-46.
. Van der Heijde D., Lie E., Kvien T.K. et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis +2009; 68: 1811-8.
. Van der Heijde D., Landewe R., Baraliakos X. et al. Ankylosing spondylitis study for the Evalution of Recombinant infliximab therapy study group. Radiographic findings 2 years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum +2008; 58: 3063-70.
. Van der Heijde D., Landewe R., Einstein S. et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment etanercept. Arthritis Rheum +2008; 58: 1324-31.
